Edinburgh-based biotechnology company Medannex today announced it has been awarded £97,000 in Scottish Enterprise SMART funding to develop a novel antibody drug conjugate (ADC) to treat pancreatic cancer and other tumours that present a critical unmet medical need.
For full details please click here.